Missouri measure would enact drug program for dying patients - PBS
Missouri is enacting a drug program for dying patients, impacting pharmaceutical manufacturers involved in drug production for this demographic.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmaceutical manufacturers, including branded drug makers and generic manufacturers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Implementation of a new drug program specifically for dying patients, which may require compliance with new regulations and practices.
Who it affects
Pharmaceutical manufacturers, including branded drug makers and generic manufacturers.
What you must do
Review and potentially adjust manufacturing practices to align with the new drug program requirements.
Deadline
Not specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- This Week at FDA: Antibiotic impurities guidance, new nitrosamine woes, and FDA’s busy calendar - RAPS
- “Hub-and-spoke” drug manufacturing set to benefit from new FDA rule - finance.yahoo.com
- After five years of attempts, Virginia on track to set up a Prescription Drug Affordability Board - virginiamercury.com
- August 29, 2022: FDA warns “Tramadol US” to stop selling controlled, unapproved drugs to U.S. residents - Partnership for Safe Medicines
- Toward Better-Quality Compounded Drugs — An Update from the FDA - nejm.org